Colchicine Dosage for Acute Gout and Prophylaxis

Acute Gout Treatment

The American College of Rheumatology recommends colchicine should be administered as a loading dose of 1.2 mg followed by 0.6 mg one hour later, with subsequent prophylactic dosing of 0.6 mg once or twice daily until the attack resolves for patients with acute gout attacks, with patients with severe renal impairment requiring dose reduction to a single dose of 0.6 mg with no repeat treatment for at least two weeks 1, 2, 3
Colchicine should only be used for gout attacks with onset within the previous 36 hours 1, 2
The FDA-approved regimen is 1.2 mg at first sign of flare, followed by 0.6 mg one hour later 1, 2
After the initial doses, continue with prophylactic dosing of 0.6 mg once or twice daily (12 hours after the initial doses) until the gout attack resolves 1, 2

For gout flare prophylaxis, the recommended dose is 0.6 mg once or twice daily 1, 4
Prophylaxis should be initiated with or just prior to starting urate-lowering therapy 4
Continue prophylaxis for at least 6 months, or 3 months after achieving target serum urate (if no tophi detected on physical exam), or 6 months after achieving target serum urate (if tophi are present) 4

Dose reduction is required with concomitant use of moderate to high potency inhibitors of CYP3A4 and P-glycoprotein 1, 2
Major interactions include clarithromycin, erythromycin, cyclosporine, and disulfiram 1, 2
Delaying treatment beyond 36 hours after symptom onset significantly reduces effectiveness 1, 5
Colchicine should not be used in high doses for acute gout due to potential toxicity; the low-dose regimen (1.8 mg total over 1 hour) is as effective as higher doses with significantly fewer side effects 5, 6

The European League Against Rheumatism recommends continuing prophylaxis for at least 6 months after starting urate-lowering therapy in patients with gout, with a minimum duration of 6 months 7

The European League Against Rheumatism suggests that colchicine should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) and considers alternative prophylaxis with low-dose NSAIDs or corticosteroids 7
The American College of Rheumatology recommends reducing the colchicine dose to 0.3 mg daily in patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) 7

The European League Against Rheumatism recommends using low-dose NSAIDs with proton pump inhibitor or low-dose prednisone ≤10 mg/day as alternative prophylaxis when colchicine is contraindicated or not tolerated 7

The American College of Rheumatology recommends monitoring patients on colchicine prophylaxis for neurotoxicity and myotoxicity, especially in patients with renal impairment or concurrent statin therapy 7

The American College of Rheumatology recommends a dose of 0.6 mg once or twice daily for gout flare prophylaxis, with a maximum daily dose of 1.2 mg/day, which represents first-line prophylaxis with Level A evidence 8, 9

The American College of Rheumatology suggests starting prophylaxis with or just prior to initiating urate-lowering therapy, due to high flare rates during early treatment, with Level A evidence 8, 9

The duration of prophylaxis should be the greater of at least 6 months, or 3-6 months after achieving target serum urate, depending on the presence of tophi, with Level A, B, and C evidence respectively 8, 9

If colchicine is contraindicated, not tolerated, or ineffective, the American College of Rheumatology recommends using low-dose NSAIDs or low-dose prednisone or prednisolone as second-line options, with Level C evidence 8, 9

The American College of Rheumatology advises against stopping prophylaxis too early, as premature discontinuation leads to increased flare rates, and recommends continuing for the full recommended duration based on tophi status and serum urate goals, with Level A evidence 8, 9
The American College of Rheumatology also recommends against using high-dose corticosteroids for prophylaxis, as doses above 10 mg/day are inappropriate and carry significant long-term risks, with Level A evidence 8, 9